ADC Deals Are Up 1900% in 2026 — Here's the Data

Twenty ADC deals closed between February 28 and August 28, 2026 — a 1900% increase over the single deal recorded in the prior six-month window (August 28, 2025 to February 28, 2026). This is not a gradual warming. This is a land grab, driven by Big Pharma's realization that its first-generation ADC portfolios are insufficient to defend oncology franchises past 2030, and that the next wave of conjugate technology — novel linker-payloads, bispecific antibody scaffolds, conditionally active constructs — is sitting inside small biotechs that won't stay independent for long.

The Data — ADC Deal Activity, Period over Period

A 20x jump in six months demands more than a headline — it demands context. The prior period's single deal was an outlier low, compressed by a market that was digesting the post-Enhertu recalibration and waiting for clinical readouts from second-generation programs. But even accounting for that trough, 20 deals in six months represents the highest ADC licensing velocity we've tracked on the Deal Benchmarks platform. The dam didn't crack — it failed structurally.

What's Driving the Trend

Pipeline gaps are the primary accelerant. AstraZeneca and Daiichi Sankyo's dominance with Enhertu forced every top-20 pharma company to answer the same board-level question: what is our ADC strategy? By mid-2025, most had answered with early-stage internal programs. By early 2026, clinical data from those programs proved underwhelming relative to the next-generation platforms emerging from China, the UK, and specialist US biotechs. The buy-versus-build calculus flipped hard toward licensing.

Payload and linker innovation created a new competitive surface. The ADC deals closing in 2026 are qualitatively different from the HER2- and Trop-2-focused transactions of 2020–2023. Buyers are now chasing topoisomerase I inhibitor alternatives, immunostimulatory payloads, protein degrader conjugates, and dual-payload architectures. This technical diversification expanded the addressable deal landscape — there are simply more differentiated assets worth licensing. The result: more deals, at higher valuations, with broader indication rights.

Regulatory confidence is also a factor, though secondary. The FDA's approval of multiple ADCs across solid and hematologic indications over 2024–2025 reduced the regulatory risk discount that buyers historically applied to conjugate programs. Pharma BD teams are now modeling ADC assets with approval probabilities closer to mAb benchmarks, which mathematically supports larger upfronts and total deal values. When your risk-adjusted NPV model improves by 15–20%, deal velocity follows.

Notable Deals

The Hansoh–GSK deal is the benchmark transaction of this cycle. A $185M upfront on a $1.7B total deal value signals that GSK is paying real money for clinical-stage conjugate assets, not optionality on preclinical platforms. The 10.9% upfront-to-TDV ratio sits right at the median for oncology licensing deals in 2026 per our Deal Benchmarks data — GSK paid market rate, which itself is a statement: this is a competitive process, not a distressed sale.

Novartis executed two separate transactions with Myricx Bio on the same day — a $1.1B and a $1.5B TDV deal. The dual-deal structure suggests Novartis is licensing distinct platform components or indication-specific rights rather than acquiring the whole company. This is a pattern we're seeing more frequently in ADC licensing 2026: pharma companies are slicing rights more finely to manage risk while locking up competitive positions. Undisclosed upfronts on $1B+ TDV deals typically indicate milestone-heavy structures with lower initial cash outlay — a sign that Novartis is managing capital discipline while still moving aggressively on pipeline expansion.

Biocytogen's deals with Whitehawk are interesting for a different reason. The $500M TDV with an undisclosed upfront — alongside a second deal with no disclosed TDV — suggests a smaller or less conventional acquirer is building an ADC-focused portfolio through platform licensing. These are not the mega-deals that dominate headlines, but they represent the broadening of ADC deal activity beyond the top-10 pharma buyers. When mid-cap and specialty acquirers start competing for conjugate assets, the supply-demand imbalance tightens further.

What This Means for BD Teams Right Now

This is a seller's market — with caveats. If you hold a differentiated ADC asset with clinical data (Phase I dose-escalation or better), you have leverage. Twenty deals in six months means multiple buyers are actively sourcing, and competitive tension is real. But "differentiated" is doing heavy lifting in that sentence. Me-too HER2 or Trop-2 ADCs with standard DXd payloads are not commanding premiums. The deals pulling $1B+ TDV involve novel targets, next-generation payloads, or proprietary linker chemistry. Know what makes your asset distinct, and price accordingly.

For buyers: speed matters more than perfection. The Novartis dual-deal approach is instructive — rather than spending 12 months on exclusive diligence for a single platform, Novartis executed two deals simultaneously to cover its strategic gaps. BD teams that are still running sequential evaluations of ADC targets will find themselves outbid or excluded from competitive processes. Consider parallel diligence tracks and pre-negotiated term sheets to compress timelines.

Deal structures are shifting toward milestone-heavy models with co-development options. Several of the Q2/Q3 2026 deals feature undisclosed upfronts against large TDVs, which typically means 8–12% upfront ratios with significant clinical and regulatory milestones. Opt-in rights at Phase II data readouts are appearing more frequently, allowing buyers to limit early capital deployment while retaining the ability to acquire full rights after proof-of-concept. If you're structuring an ADC deal today, run your terms through the Ambrosia calculator to see where your upfront-to-TDV ratio falls relative to the current 2026 cohort.

One more tactical point: geography matters. Three of the five notable deals in this cycle involve Chinese-origin biotechs (Hansoh, Biocytogen). China-to-global licensing for ADC assets has accelerated faster than any other modality class. If your BD team doesn't have a China sourcing strategy — relationships with Chinese biotechs, familiarity with NMPA regulatory pathways, and comfort with cross-border deal structures — you are leaving the richest vein of ADC innovation untapped.

Benchmark your deal against current market rates. Whether you're structuring an ADC out-license or evaluating an in-licensing opportunity, the terms that made sense in 2024 are already stale. Use the Ambrosia calculator to compare your upfront, milestones, royalties, and TDV against the latest ADC deal cohort — and negotiate from data, not intuition.